Tag: Humacyte
Humacyte ATEV meets primary endpoints in V007 Phase 3 clinical trial...
Humacyte has announced positive top-line results from the V007 Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV) in arteriovenous access for...
Data on Humacyte human acellular vessel published
Humacyte, a clinical-stage biotechnology platform company developing "universally implantable, bioengineered human tissue at commercial scale", has announced in a press release the publication of...
A raft of new directions for vascular access grafts
A departure from the “extreme mantra” of Fistula First unlocks the door to a new, dynamic vision that could swing the pendulum back to...
Bright future for access grafts highlighted at VASBI 2021 with multiple...
New technologies intended to improve the often-mixed outcomes associated with arteriovenous grafts (AVGs) for haemodialysis access were on display at this year’s Vascular Access...
Humacyte to present long-term follow-up data from Phase 2 vascular access...
Humacyte has announced that the clinical results of five-year outcomes in patients receiving the human acellular vessels (HAV) for arteriovenous (AV) access in haemodialysis...